Biophytis Completes €5.3 Million Capital Increase to Fund Obesity Trial

Biophytis has completed a €5.3 million capital increase to support its Phase 2 clinical trial targeting obesity. The funding, sourced from European and US institutional investors, secures the trial until mid-2028. This is achieved through the issuance of over 101 million new shares and associated warrants.

The funds raised will primarily drive the obesity trial's execution across the US, EU, and Brazil while sustaining company operations into Q1 2028. Additionally, proceeds also address Biophytis' remaining debt obligations with Hexagon, reducing the outstanding balance significantly.

This trial aims to assess Biophytis’ BIO101 drug as a potential adjunct to existing GLP-1 receptor therapies, emphasizing the preservation of muscle strength during weight loss. The Phase 2 study is expected to launch in Q1 2027, with first results anticipated in the first half of 2028.